Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd

NCT04829604 is registered in ClinicalTrials.gov with Ambrx, Inc. as lead sponsor.

NCT NCT04829604
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04829604 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Global, Phase 2 Study of ARX788 in HER2-positive Metastatic Breast Cancer Patients Who Were Previously Treated With T-DXd
Lead sponsor
Ambrx, Inc.
Phase
Phase 2
Overall status
Active, not recruiting
Start date
October 26, 2021
Completion date
June 30, 2027
Enrollment
72 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

her2 positive metastatic breast cancer